My Email to Pharmagap (REPLIES)(AWAITING NEXT REPLY) I took email addresses out to avoid spam bots.
Thank you Simon for your prompt and understanding reply.
When I refer to ROADSHOW, I am referring of the marketing blitz that could be happening behind the scenes to get more investors interested in the company. I worked for a hedge fund in the Ottawa area, I helped in the day to day operations of the fund, along with marketing to large institutional investors through our investment association (AIMA). Along with our institutional marketing, our fund manager would be promoting the company at every opportunity, whether we were raising money in Private Placements, taking companies to the pinks, or just entertaining clients, we always had our company in the foreground to all marketing activities, and slowly gained additions subscriptions into our fund.
As SC Stormont seems to be the “LARGE” institutional investor relying on them is not the solution to taking Pharmagap to a level that could and would yield positive returns for investors. Is it not be possible to pull on the network developed by McInnes, Bryden and crew to attract more attention, or perhaps through your personal network or even OCRI?
I can see having a share price greater than $ 1.00 be better for ongoing operations. Private placements would be easier to achieve, without the mass dilution that could be incurred at these levels. As Pharmagap gets closer and closer to potential human trials, the 1.5 – 2.0 MM required to go through that next phase will cost us investors too greatly in dilution, for it to make sense.
On May 29th, 2006 it was said a licencing agreement was 6 months away, what has happened to that, and is this still actively in the works?
Thank you,
#####
------------------------------------------------------------------------------------------------------------------
From: Simon Goulet
Sent: Wednesday, October 28, 2009 12:33 PM
To:
Subject: RE: Shareholders Value
Hi ##### Thanks for your note below.
We have reached out in a variety of ways the past few months to investors (newsletter, mass emailings, company, local radio and newspaper interviews etc). I must tell you however that it’s not easy to get picked up by the media outlets – BNN for example wants companies with a share price > $1.
I do share your frustration with the Stomont selling – however as you said its within his right to do so due to his personal situation.
What road show are you referring to?
Simon Goulet
EVP & Chief Operating Officer
100 Sussex Drive Ottawa Ontario K1A 0R6 Canada
Tel: (613)991-5370 Fax: (613)998-3399
---------------------------------------------------------------------------------------------------
Sent: October 27, 2009 9:48 PM
To:
Subject: Shareholders Value
Hi,
As an investor in Pharmagap, I have a few concerns with the lack of investor interest in a company that has such upside potential.
1. I don’t think management has taken the opportunity to promote the results, and/or company. As an investor, who is holding a small number of shares (76’500) that actively promoted the company, results and shares research information to my network (400’000 shares) I am disappointed in the lack of promotion there has been for your company, whether it be print, radio, or television I don’t think the word on PHARMAGAP has hit investors. Although different companies, I look at another holding of mine, BioExx (BXI.V) and the number of investors that know of the company, recognize the potential, is astounding and they seem to be discuss amongst investors.
2. I don’t want to question his personal mandate, but the timing of his last 2 sell offs, has coincided perfectly with news being released, and that has alarms being raised. Especially for new entrants into the shares. I recognize that Mr. Bryden has financial obligations that he must attend to, and selling shares in Pharmagap is a last resort, as said in one of the latest news releases. But, without the confidence from the insiders when it comes to the company, or seemingly the results, Mr Brydens actions are specifically driving investors away from a potentially lucrative investment.
Perhaps you can shed some light to the ongoing roadshow that is being done to get investors interested in this company. More importantly, institutional investors.
Thank you,